The status of the Depo-Provera meningioma lawsuits against Pfizer will be addressed by Anapol Weiss shareholder Tracy Finken Magnotta at the HarrisMartin MDL CLE Conference on Wednesday, December 4, in New York City. Magnotta and her team at Anapol Weiss filed one of the first lawsuits against Pfizer, alleging that the company failed to warn Depo-Provera users about the increased risk of developing meningioma tumors with prolonged use of the injectable contraceptive. Anapol Weiss is actively investigating additional claims and preparing to file more lawsuits against Pfizer on behalf of individuals who have developed meningiomas after using Depo-Provera.
Tracy Finken Magnotta has a proven track record of success in mass tort and pharmaceutical litigation. She serves in leadership roles in the proton pump inhibitor (PPI), Tepezza and Zantac litigation. She has also played a significant role in cases involving JUUL, herbicide exposure, medical devices, and other defective products that caused injuries to individuals nationwide. Her extensive experience managing complex litigation makes her a sought-after speaker and authority on multidistrict litigation strategies.
In addition to providing an update on the Depo-Provera lawsuits, Magnotta will also speak at the conference about the importance of state court parallel actions during an ongoing MDL.
For more information about the event or to register, visit the HarrisMartin website.
About Anapol Weiss
Anapol Weiss is a nationally recognized personal injury law firm with a focus on mass tort, pharmaceutical litigation, medical malpractice, and product liability cases. Established in 1977, the firm is committed to achieving justice for individuals and families who have suffered harm due to negligence or defective products.
